Dr. Lu has served as our CEO since he co-founded Senti Bio in 2016. Since 2010, Dr. Lu has been an MIT faculty member in the departments of Biological Engineering and Electrical Engineering and Computer Science. In addition, Dr. Lu has been a co-founder and a Scientific Advisory Board member to a number of biotechnology and biopharmaceutical companies, including BiomX, Corvium, Eligo Bioscience, Engine Biosciences, Synlogic and Tango Therapeutics.

Dr. Lu earned his M.D. from Harvard Medical School and his Ph.D. in Electrical and Biomedical Engineering from Massachusetts Institute of Technology as part of the Harvard-MIT Health Sciences and Technology Medical Engineering and Medical Physics Program. Dr. Lu has extensive experience in the field of synthetic biology and has received numerous awards: NIH New Innovator Award, US President Early Career Award for Scientists and Engineers, MIT Technology Review’s TR35, Navy and Army Young Investigator Prizes and others.

Mr. Cross serves as the Chief Financial Officer of Senti Bio, where he oversees the company’s financial strategy, operations, and investor relations. His leadership plays a key role in supporting the company’s ongoing growth and clinical development. Prior to joining Senti, Mr. Cross was the Chief Financial Officer at Sonnet BioTherapeutics, where he managed the financial operations of the company, oversaw investor relations and directed the capital markets and investment banking initiatives.

As a complement to his corporate experience, Mr. Cross enjoyed a 20-year career on Wall Street, where he served as a managing director in the healthcare investment banking practice at Chardan, in addition to working as a professional investor on globally diversified healthcare portfolios at several funds, including SAC Capital, Citadel, and Balyasny Asset Management. Mr. Cross launched his career in finance covering biotechnology for the equity research divisions at Hambrecht & Quist and Goldman Sachs. He earned a Master of Public Health from the Yale University School of Medicine and a Bachelor of Science in psychology from Washington & Lee University.

Dr. Rajangam is responsible for leading the development and regulatory strategy to rapidly advance Senti Bio’s off-the-shelf CAR-NK cell oncology programs into and through clinical development. Dr. Rajangam served in leadership roles at various biotech companies, most recently Nkarta Therapeutics where, as chief medical officer, she was responsible for clinical development of CAR-NK cell therapies for oncology. Prior to Nkarta, she was chief medical officer at Atara Biotherapeutics where she led the development of T-cell therapies for oncology, neurology and infectious diseases. Prior to that, Dr. Rajangam was chief medical officer of Cleave Biosciences, where she led oncology clinical development programs. Prior to becoming a chief medical officer, Dr. Rajangam gained relevant senior leadership experience at Onyx and Exelixis, while contributing to the clinical development and global approval of several marketed oncology products including Kyprolis®, Cotellic® and Cometriq®/Cabometyx®. Dr. Rajangam currently serves on the board of directors of Turnstone Biologics, a clinical-stage biotechnology company developing next-generation tumor infiltrating lymphocyte cell therapies and oncolytic virus cancer immunotherapies.

Dr. Rajangam received a medical degree from St. Johns’ Medical College and completed her surgical residency with a focus on oncology at the Postgraduate Institute of Medical Education and Research (PGIMER), both in India. She received a Ph.D. in biomedical cell and tissue engineering from Northwestern University.

Mrs. Alford has been leading Senti’s R&D and clinical operations since 2022. She brings over 20 years of clinical operations experience, including departmental build outs and trial progression from First in Human/Phase I to registration. Prior to joining Senti, Mrs. Alford held various clinical roles at Kronos Bio, Peloton Therapeutics (acquired by Merck), and Reata Pharmaceuticals. She was also a clinical research consultant advising a number of companies on clinical development, strategy, and operations.  Mrs. Alford was part of the clinical teams for several FDA-approved products, including WELIREG® for the treatment of von Hippel-Lindau (VHL)-associated renal cell carcinoma.

Mrs. Alford earned a master’s degree in Clinical, Counseling and Applied Psychology from Northwestern University, and a bachelor’s degree in Biology & Psychology from Rhodes College.

Mr. Chung joined Senti Bio in 2022 and brings 15 years of investing, operations, board and advisory experience from a broad set of industries including life sciences, healthcare, technology, and consumer/retail. As an investor, he was responsible for the identification, evaluation, structuring, execution, and management of control-oriented equity and debt investments, working hand-in-hand with management teams and through board roles to drive value creation.

Mr. Chung began his career at UBS Investment Bank, in the Financial Sponsors, Leveraged Finance & Restructuring Group, where he worked on debt-financed transactions and restructuring advisory services related to over $25 billion of securities. Subsequently, he focused on investing roles at Health Evolution Partners, a $500 million operations-oriented private equity fund focused on high-growth healthcare businesses, and the mezzanine group at Crescent Capital Group, a $3 billion fund focused on high-yield debt and equity investments. Across his investment experience, Mr. Chung was responsible for managing over a dozen portfolio companies, including the sale of 5, altogether worth nearly $1 billion of invested capital.

Mr. Chung earned his BS in Biomedical Computations and BA in Economics, both from Stanford University.

Mr. Cutler has served as our SVP – Head of Legal Affairs since November 2024. From 2021 to November 2024, Mr. Cutler served as Chief Legal Officer for Telesis Bio Inc. From 2016 to 2021, Mr. Cutler served as General Counsel for Synthetic Genomics, Inc. (now Viridos, Inc.). From 2012-2015, Mr. Cutler was General Counsel for LifeVantage Corporation, a public dietary supplement company. Prior to LifeVantage, Mr. Cutler served as Vice President, Business Development for Somaxon Pharmaceuticals after spending 9 years at Biogen Idec (now Biogen) in a variety of legal and business development roles. Mr. Cutler began his career in two large law firms focusing his practice on private and public biotech clients. Mr. Cutler earned a Juris Doctorate from Brigham Young University and a Bachelor of Arts in Finance from the University of Utah.

Dee Olomajeye Dragon joined Senti Bio in 2019 and is responsible for all facets of Senti’s People (HR) strategy, with Diversity, Inclusion, and Culture as key building blocks in designing Senti’s employee experience to drive business success. Mrs Dragon is a business strategist with a People/HR lens, leading Senti’s efforts to deliver on the promise of the top talent the company attracts.

Prior to her role at Senti, Mrs. Dragon worked as a Senior Consultant in the Benefits & Total Compensation field, most recently serving as Assistant Vice President with Aon’s Health & Benefits Solutions Practice in San Francisco. In this role, Dee helped her clients develop people strategies and deploy programs in the areas of Total Rewards, Employee Experience Curation, Culture Building and Diversity, Equity & Inclusion.

Mrs. Dragon’s professional journey includes stints in Brussels, Chicago & Los Angeles, and professional tenures at Mercer Human Resource Consulting, The Los Angeles Times, and Willis Towers Watson.

Mrs. Dragon received her B.F.A. Degree in Electronic Media Communications from The University of Cincinnati, and a Certificate in Strategic Change Management from Kellogg School of Business at Northwestern. She resides in the San Francisco Bay Area. 

Dr. Garrison joined Senti Bio in 2016, where he has continually applied his 25 years of cell & gene therapy experience towards the successful development and clinical application of Senti’s Gene Circuit technologies to develop truly innovative medicines with the ability to target diseases in a more focused, controlled, and effective manner. Dr. Garrison currently leads both the Discovery Research and Translational Science Teams at Senti.

Dr. Garrison earned his B.S. in Microbiology (minor: Comparative Literature) from University of California, Davis, and a Ph.D. in human gene therapy from Stanford University, then completed 2 postdoctoral fellowships (Harvard University & Harvard Medical School) focused on stem cell biology, leukemia,
genome editing, and TGFβ, with numerous high impact publications, fellowship, grant, and contract awards.

Mr. Siddiqui brings over 27 years of biopharmaceutical experience with a proven track record in novel modalities and exceptional leadership to Senti, where he is responsible for technical operations including process development, manufacturing and supply chain. Previously, Mr. Siddiqi was SVP Manufacturing Operations at IGM Biosciences where he oversaw end-to-end manufacturing operations, clinical supply chain, and drug product development.

Mr. Siddiqui also held key leadership roles at Instil Bio, Kite Pharma, and Genentech, where he led process development, technology transfers, and manufacturing operations for all phases of development across multiple geographies where he was instrumental in developing CMC strategies, driving operational efficiencies, building high-performance teams, and cultivating strong stakeholder collaboration. Mr. Siddiqui holds an MBA from Saint Mary’s College of California and a Bachelor of Science in Biochemistry from the University of California, Davis.